Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC14 in Acute Respiratory Distress Syndrome
NCT03017547Phase 2Withdrawn
- Sponsor
- Implicit Bioscience
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of atibuclimab in acute respiratory distress syndrome (ARDS), sponsored by Implicit Bioscience. Planned start Jun 2019; status: withdrawn.
02
Drugs
atibuclimab
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03017547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017547.